Tools for Practice Outils pour la pratique


#421 Happiness is a Dry Bed: Desmopressin for pediatric nocturnal enuresis


CLINICAL QUESTION
QUESTION CLINIQUE
Does desmopressin reduce bedwetting for children with nocturnal enuresis?


BOTTOM LINE
RÉSULTAT FINAL
Desmopressin increases the proportion of children achieving 14 consecutive dry nights (“complete response”) at 2 weeks from 10% (placebo) to 32%. Desmopressin also decreases wet nights by ~2 per week over placebo with similar adverse effects.  Short-term efficacy is similar to enuresis alarms but alarms may have lower relapse rates. More children will have complete response with desmopressin-alarm combination (53%) versus desmopressin alone (42%).



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • Results statistically significant unless stated.
  • Most recent systematic review of randomized controlled trials (RCTs). Ages 5-16 years.1
    • Desmopressin 100-800mcg orally versus placebo:
      • “Complete response” (14 consecutive dry nights); (11 RCTs, 922 patients). At 14 days:
        • 32% versus 10% (placebo); number needed to treat (NNT)=5.
        • Lower and higher doses: No difference.
      • Mean wet nights (16 RCTs, 1267 patients, baseline: 5). At 28 days:
        • ~1.8 fewer nights/week over placebo.
      • Adverse effects: No difference.
    • Desmopressin (intranasal/oral) versus enuresis alarm. At 3 months:
      • Complete response (15 RCTs, 1530 patients):
        • No difference.
      • Relapse after discontinuation (6 RCTs, 685 patients):
        • 67% versus 56% (alarm); number needed to harm (NNH)=9.
    • Desmopressin plus alarm versus desmopressin:
      • Complete response (5 RCTs, 370 patients). At 4 months:
        • 53% versus 42% (desmopressin); NNT=10.
      • Mean wet nights (2 RCTs, 156 patients). At 84 days:
        • Combination: ~0.9 fewer nights/week.
      • Relapse after discontinuation (2 RCTs, 161 patients). At 12 weeks:
        • 68% versus 86% (desmopressin); NNT=6.
    • Desmopressin plus alarm versus alarm:
        • Mean wet nights (6 RCTs, 528 patients). At 70 days:
          • Combination: ~0.8 fewer nights/week.
  • Other systematic reviews2,3 and newer RCTs found similar.4
  • Limitations: Many small RCTs with selective outcome reporting.

CONTEXT
CONTEXTE
  • Guidelines:5
    • Education first-line, alarms second-line.
    • Then desmopressin intermittently (e.g., sleepovers); daily if needed (consider electrolyte monitoring every 3 months).
    • Trial discontinuation every 3 months.5
  • Desmopressin may work on first night.1 Dose 30-60 minutes before bed.5
  • To avoid water toxicity:
    • Limit fluids from one hour before dosing until morning: ~200mL.5
    • Intranasal spray not recommended.5-6
  • 120mcg melt=200mcg tablet.5
  • Cost (30-day):7
    • 200mcg tablet: ~$55.
    • 120mcg melt: ~$100.


Latest Tools for Practice
Derniers outils pour la pratique

#421 Happiness is a Dry Bed: Desmopressin for pediatric nocturnal enuresis

Does desmopressin reduce bedwetting for children with nocturnal enuresis?
Read Lire 0.25 credits available Crédits disponibles

#420 Scratching the Surface: What is the most effective treatment for scabies?

For adults and children with classic scabies, how effective are treatment options and what is the duration of treatment?
Read Lire 0.25 credits available Crédits disponibles

#419 Vitamin B12 Deficiency: Monthly shots or daily pills?

In patients with vitamin B12 deficiency, is oral vitamin B12 as effective as intramuscular (IM) vitamin B12?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Jen Potter MD CCFP
  • Allison Paige MD CCFP
  • Adrienne J Lindblad BSP BSc ACPR PharmD
  • Tony Nickonchuk BSc Pharm

1. Hahn D, Stewart F, Raman G. Cochrane Database Syst Rev. 2025 Jul 29;7(7): CD002112.

2. Peng CCH, Yang SSD, Austin PF, et al. Sci Rep. 2018;8(1): 16755.

3. Zhai Y, Zhang Y, Gou H. Pediatr Nephrol. 2025;40(9): 2795-2806.

4. Lv L, Zhang Y, Li Q, et al. Sleep Med. 2025;136: 106849.

5. Harris J, Lipson A, Dos Santos J. Paediatr Child Health. 2023;28(6): 362-8.

6. Dehoorne JL, Raes AM, Van Laecke E, et al. J Urol. 2006;176(2): 754-8.

7. Author’s calculations from Alberta Blue Cross Interactive Drug Benefit List. Available at: https://idbl.ab.bluecross.ca/idbl/load.do. Accessed Mar 4, 2026.

Authors have no conflicts of interest to declare.